Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acolbifene - Endoceutics

Drug Profile

Acolbifene - Endoceutics

Alternative Names: Acolbifene hydrochloride; EM 652.HCl; EM-652; SCH 57068; SCH 57068.HCl

Latest Information Update: 09 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endoceutics
  • Developer Endoceutics; National Cancer Institute (USA)
  • Class Antineoplastics; Benzopyrans; Osteoporosis therapies; Phenyl ethers; Piperidines
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Oct 2015 No recent reports on development identified - Phase-II for Breast cancer (Prevention) in USA (PO)
  • 23 Jul 2015 Further phase III development for Breast cancer is pending as Endoceutics seeks a partner for out-licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top